AN2 Therapeutics, Inc.

NasdaqGS:ANTX Stock Report

Market Cap: US$71.6m

AN2 Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

NasdaqGS:ANTX Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
18 Jan 24SellUS$1,911,410Joseph ZakrzewskiIndividual100,000US$19.11
16 Jan 24SellUS$1,965,000Adjuvant Capital, LPCompany100,000US$19.65
12 Jan 24SellUS$15,753Mountain Group Capital, LLCCompany719US$21.91
23 Aug 23SellUS$6,400Adjuvant Capital, LPCompany400US$16.00
18 Aug 23BuyUS$16,000,002RA Capital Management, L.P.Company1,777,778US$9.00
15 May 23BuyUS$53,770Eric EasomIndividual10,000US$5.38

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of ANTX?
Owner TypeNumber of SharesOwnership Percentage
Private Companies630.000211%
General Public1,767,2035.92%
Individual Insiders1,768,5605.93%
Public Companies2,410,9788.08%
Hedge Funds3,120,80510.5%
Institutions10,158,42734.1%
VC/PE Firms10,603,00435.5%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 53.5%.


Top Shareholders

Top 25 shareholders own 90.8% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
18.6%
RA Capital Management, L.P.
5,551,295US$13.3m0%0.18%
8.98%
TCG Crossover Management, LLC
2,678,209US$6.4m0%0.57%
7.96%
Adjuvant Capital, LP
2,373,500US$5.7m-4.04%no data
5.24%
BVF Partners L.P.
1,563,963US$3.8m0%0.09%
5.22%
Citadel Advisors LLC
1,556,842US$3.7m0.02%no data
4.99%
Frazier Life Sciences Management, LP
1,488,889US$3.6m7.2%0.15%
4.57%
Pfizer Inc.
1,362,499US$3.3m0%no data
4.29%
Janus Henderson Group plc
1,279,975US$3.1m-7.85%no data
4.06%
Eric Easom
1,212,012US$2.9m-0.23%no data
3.82%
Avidity Partners Management, L.P.
1,140,000US$2.7m4.64%0.1%
3.53%
The Vanguard Group, Inc.
1,052,591US$2.5m12%no data
3.51%
Brii Biosciences Limited
1,048,479US$2.5m0%no data
3.02%
Adage Capital Management, L.P.
900,672US$2.2m-0.54%no data
3.02%
Mountain Group Capital, LLC
899,861US$2.2m-0.56%100.0%
2.23%
Octagon Capital Advisors LP
664,575US$1.6m-23.4%0.28%
1.69%
Joseph Zakrzewski
504,079US$1.2m-16.6%no data
1.13%
Marshall Wace LLP
337,321US$809.6k-52.9%no data
1.03%
BlackRock, Inc.
305,841US$734.0k625%no data
0.83%
Nantahala Capital Management, LLC
248,278US$595.9k-30.4%0.06%
0.63%
T. Rowe Price Group, Inc.
187,399US$449.8k0%no data
0.6%
Geode Capital Management, LLC
178,623US$428.7k99.2%no data
0.54%
Citigroup Inc.,Banking and Securities Investments
160,486US$385.2k0.87%no data
0.53%
Invesco Capital Management LLC
157,891US$378.9k-16%no data
0.44%
Acuta Capital Partners, LLC
132,000US$316.8k892%0.21%
0.33%
Susquehanna International Group, LLP, Asset Management Arm
99,404US$238.6k310%no data
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.